{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:19:26Z","timestamp":1769203166279,"version":"3.49.0"},"reference-count":48,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,3,25]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess how achievement of increasingly stringent clinical response criteria and disease activity states at week 52 translate into changes in core domains in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients in BE MOBILE 1 and 2 achieving different levels of response or disease activity (Assessment of SpondyloArthritis International Society (ASAS) and Ankylosing Spondylitis Disease Activity Score (ASDAS) response criteria, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50)) at week 52 were pooled, regardless of treatment arm. Associations between achievement of these endpoints and change from baseline (CfB) in patient-reported outcomes (PROs) measuring core axSpA domains, including pain, fatigue, physical function, overall functioning and health, and work and employment, were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Achievement of increasingly stringent clinical efficacy endpoints at week 52 was generally associated with sequentially greater improvements from baseline in all PROs. Patients with nr-axSpA achieving ASAS40 demonstrated greater improvements (CfB) than patients who did not achieve ASAS40 but did achieve ASAS20, in total spinal pain (\u22125.3 vs \u22122.8, respectively), Functional Assessment of Chronic Illness-Fatigue subscale (12.7 vs 6.7), Bath Ankylosing Spondylitis Function Index (\u22123.9 vs \u22121.8), European Quality of Life 5-Dimension 3-Level Version (0.30 vs 0.16), Work Productivity and Activity Impairment-axSpA presenteeism (\u221235.4 vs \u221215.9), overall work impairment (\u221236.5 vs \u221212.9), activity impairment (\u221239.0 vs \u221221.0) and sleep (9.0 vs 3.9). Results were similar for ASDAS and BASDAI50. Similar amplitudes of improvement were observed between patients with nr-axSpA and r-axSpA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients treated with bimekizumab across the full axSpA disease spectrum, who achieved increasingly stringent clinical response criteria and lower disease activity at week 52, reported larger improvements in core axSpA domains.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-004040","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T13:25:51Z","timestamp":1712755551000},"page":"e004040","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"first","affiliation":[{"name":"Department of Rheumatology, La Paz University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"School of Medicine, Swedish Medical Center and University, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[{"name":"Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenh\u00f6he, Bielefeld, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[{"name":"PCOM Analytics, Avallon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fleurinck","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB Pharma, Colombes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"M\u00f8rup","sequence":"additional","affiliation":[{"name":"UCB Pharma, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-4260","authenticated-orcid":false,"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"2025090312254987000_10.2.e004040.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2025090312254987000_10.2.e004040.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"2025090312254987000_10.2.e004040.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2025090312254987000_10.2.e004040.4","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00194-8"},{"key":"2025090312254987000_10.2.e004040.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2025090312254987000_10.2.e004040.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025090312254987000_10.2.e004040.7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of Ixekizumab in the treatment of radiographic axial Spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"2025090312254987000_10.2.e004040.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"2025090312254987000_10.2.e004040.9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial Spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"The Lancet"},{"key":"2025090312254987000_10.2.e004040.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"2025090312254987000_10.2.e004040.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216118"},{"key":"2025090312254987000_10.2.e004040.12","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an Interleukin-17A antagonist in the treatment of Ankylosing Spondylitis or radiographic axial Spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der","year":"2018","journal-title":"The Lancet"},{"key":"2025090312254987000_10.2.e004040.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"2025090312254987000_10.2.e004040.14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of Upadacitinib in patients with active Ankylosing Spondylitis (SELECT-AXIS 1): a Multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"The Lancet"},{"key":"2025090312254987000_10.2.e004040.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2025090312254987000_10.2.e004040.16","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1093\/rheumatology\/keaa527","article-title":"Which disease activity outcome measure discriminates best in axial Spondyloarthritis? A systematic literature review and meta-analysis","volume":"59","author":"Ortolan","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312254987000_10.2.e004040.17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial Spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2025090312254987000_10.2.e004040.18","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","article-title":"The ASAS-OMERACT core domain set for axial Spondyloarthritis","volume":"51","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312254987000_10.2.e004040.19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/rheumatology\/keaa353","article-title":"Determinants of the patient global assessment of well-being in early axial Spondyloarthritis: 5-year longitudinal data from the DESIR cohort","volume":"60","author":"Hirano","year":"2021","journal-title":"Rheumatology"},{"key":"2025090312254987000_10.2.e004040.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216143"},{"key":"2025090312254987000_10.2.e004040.21","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-019-0819-8","article-title":"The European map of axial Spondyloarthritis: capturing the patient perspective\u2014an analysis of 2846 patients across 13 countries","volume":"21","author":"Garrido-Cumbrera","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2025090312254987000_10.2.e004040.22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40744-020-00254-z","article-title":"Ixekizumab improves patient-reported outcomes in non-radiographic axial Spondyloarthritis: results from the coast-X trial","volume":"8","author":"Deodhar","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025090312254987000_10.2.e004040.23","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of Secukinumab on patient-reported outcomes in patients with active Ankylosing Spondylitis: A phase III randomized trial (MEASURE 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312254987000_10.2.e004040.24","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-021-00205-3","article-title":"Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V\/W 52-week results","volume":"5","author":"Deodhar","year":"2021","journal-title":"BMC Rheumatol"},{"key":"2025090312254987000_10.2.e004040.25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40744-023-00536-2","article-title":"Effect of Upadacitinib on disease activity, pain, fatigue, function, health-related quality of life and work productivity for biologic refractory Ankylosing Spondylitis","volume":"10","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090312254987000_10.2.e004040.26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002253","article-title":"Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active Ankylosing Spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Navarro-Comp\u00e1n","year":"2022","journal-title":"RMD Open"},{"key":"2025090312254987000_10.2.e004040.27","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-9-36","article-title":"Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness therapy-fatigue Subscale for patients with Ankylosing Spondylitis","volume":"9","author":"Revicki","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"2025090312254987000_10.2.e004040.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025090312254987000_10.2.e004040.29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/14712598.2022.2156283","article-title":"Emerging therapies for the treatment of Spondyloarthritides with focus on axial Spondyloarthritis","volume":"23","author":"Braun","year":"2023","journal-title":"Expert Opinion on Biological Therapy"},{"key":"2025090312254987000_10.2.e004040.30","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual Neutralisation of IL-17F and IL-17A with Bimekizumab blocks inflammation-driven Osteogenic differentiation of human Periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"2025090312254987000_10.2.e004040.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025090312254987000_10.2.e004040.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208642"},{"key":"2025090312254987000_10.2.e004040.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090312254987000_10.2.e004040.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100826"},{"key":"2025090312254987000_10.2.e004040.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2025090312254987000_10.2.e004040.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"2025090312254987000_10.2.e004040.37","first-page":"2286","article-title":"A new approach to defining disease status in Ankylosing Spondylitis: the bath Ankylosing Spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090312254987000_10.2.e004040.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev125"},{"key":"2025090312254987000_10.2.e004040.39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40273-018-0628-3","article-title":"Comparing the UK EQ-5D-3L and English EQ-5D-5L value SETS","volume":"36","author":"Mulhern","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2025090312254987000_10.2.e004040.40","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"2025090312254987000_10.2.e004040.41","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"2025090312254987000_10.2.e004040.42","unstructured":"Maruish ME . User\u2019s manual for the SF-36V2 health survey: quality metric incorporated. 2011."},{"key":"2025090312254987000_10.2.e004040.43","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2025090312254987000_10.2.e004040.44","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-021-00311-3","article-title":"The development and validation of a revised version of the medical outcomes study sleep scale (MOS sleep-R)","volume":"5","author":"Yarlas","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2025090312254987000_10.2.e004040.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224803"},{"key":"2025090312254987000_10.2.e004040.46","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210206"},{"key":"2025090312254987000_10.2.e004040.47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev267"},{"key":"2025090312254987000_10.2.e004040.48","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231189079","article-title":"Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial Spondyloarthritis","volume":"15","author":"Rudwaleit","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-004040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:26:02Z","timestamp":1756927562000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-004040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/rmdopen-2023-004040"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-004040","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}